Sign inJoin waitlistJoin the waitlist

Prajwal Dhakal

Clinical Assistant Professor · University of Iowa Health Care Medical Center

Credentials: · · · · · · · ·

History

University of Iowa Health Care Medical Center
Present
Roy J. and Lucille A. Carver College of Medicine
Present

Hematology and Medical Oncology
University of Nebraska Medical Center
2017–2020
Internal Medicine
University of Michigan Health - Sparrow
2014–2017
MBBS, Tribhuvan University, Kirtipur, Nepal
2013–2014
MBBS, Tribhuvan University, Kirtipur, Nepal
Institute of Medicine, Tribhuvan University
2009–2013

Research

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Blood · 2023 · 58 citations
Eculizumab in Transplant-Associated Thrombotic Microangiopathy
Systematic review or meta-analysis · Clinical and Applied Thrombosis/Hemostasis · 2017 · First of 4 authors · 49 citations
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Review · Blood Reviews · 2023 · First of 6 authors · 43 citations

Vijaya Bhatt
47 papers · 7 as a fellow
Krishna Gundabolu
18 papers
UJ
Utsav Joshi
11 papers · 5 as a fellow
Smith Giri
8 papers · 8 as a resident
Grerk Sutamtewagul
7 papers
Supratik Rayamajhi
7 papers
MR
Manoj Rai
6 papers · 5 as a resident
Aditya Ravindra
5 papers · 4 as a fellow
Shiva Shrotriya
5 papers · 1 as a fellow
Bunny Pozehl
4 papers
James Armitage
4 papers
KP
Kittika Poonsombudlert
4 papers · 1 as a fellow

Clinical trials

Ascorbate in Myelodysplastic Syndrome
Principal investigator · Recruiting · Phase 2
Prajwal Dhakal
2026–2029
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027